SMALL CELL LUNG CANCER

This study is testing whether a precise type of radiation called stereotactic radiosurgery (SRS) can help people with small cell lung cancer that has spread to the brain. About 62 adults with up to 20 brain tumors will receive SRS, and researchers will track how many are alive af…

This study tests whether combining two experimental drugs, ZG006 and ZG005, can shrink tumors in people with advanced small cell lung cancer or neuroendocrine carcinoma. About 350 adults aged 18 to 70 will take part. The goal is to see if the combination is safe and works better …

This study tests the drug fingolimod (currently used for multiple sclerosis) in people with advanced non-small cell or small cell lung cancer whose cancer has worsened after standard treatments. The goal is to see if the drug is safe and can shrink tumors or slow cancer growth. A…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety and find the best dose. About 470 adults will take part to see if the drug can he…

This study tests a new drug called ZG006 in people with small cell lung cancer or neuroendocrine carcinoma who have run out of standard treatments or can't tolerate them. The main goals are to find a safe dose and check for side effects. About 54 adults aged 18 to 75 will take pa…

This study tests whether adding an experimental drug called cirtuvivint to standard chemotherapy (irinotecan) can help people with small cell lung cancer that has come back after initial treatment. About 42 adults whose cancer has progressed after at least one prior therapy will …

This study tests a new drug called SKB500, given with other treatments, for people with small cell lung cancer. The goal is to see if the combination is safe and can shrink tumors or slow the cancer's growth. About 80 adults aged 18 to 75 who have had limited or no prior treatmen…

This study tests a new drug called AK112 in people with limited-stage small cell lung cancer whose tumors have not grown after standard chemotherapy and radiation. The drug targets two proteins (PD-1 and VEGF) to help the immune system fight cancer and cut off its blood supply. A…

This early-stage study tests a new drug called BL-M14D1 in about 22 people with advanced small cell lung cancer, neuroendocrine tumors, or other solid tumors that have spread and no longer respond to standard treatments. The main goals are to check the drug's safety, find the bes…

This program offers early access to the investigational drug ABBV-706 for people with small cell lung cancer who have no other suitable treatment options and cannot join a clinical trial. A doctor must decide if the potential benefits outweigh the risks. The goal is to provide tr…

This study tests a new drug, IDE849, in people with cancers that have a specific marker called DLL3, including small cell lung cancer and other solid tumors. The trial has two phases: first to check safety and find the right dose, then to see if the drug shrinks tumors or slows t…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced or spreading solid tumors that have a specific change in the TP53 gene (Y220C mutation). The goal is to see if the drug is safe and works against these cancers. About 300 adults (and some teens after …

This study tests whether adding the experimental drug tarlatamab to standard chemotherapy and immunotherapy helps people with extensive-stage small-cell lung cancer live longer. About 330 adults who have not yet been treated will be randomly assigned to receive either the new com…

This study tests two experimental drugs—MK-6070 and ifinatamab deruxtecan—alone or together, in people with advanced small cell lung cancer that came back or didn't respond to prior therapy. About 262 adults will join to see if these treatments shrink tumors and are safe. The goa…

This early-phase trial is testing whether adding acetazolamide (a drug that blocks carbonic anhydrase) to standard chemotherapy and radiation or immunotherapy can help treat small cell lung cancer. About 27 adults with either localized or extensive small cell lung cancer will tak…

This study looks at how well the drug T-DXd works in adults with advanced HER2-positive solid tumors that have spread and are not responding to other treatments. About 100 people will be followed to see if their tumors shrink and how long that lasts. The goal is to provide a trea…

This study tests a new drug, ZL-1310, designed to target and destroy cancer cells in people with small cell lung cancer that has come back after initial treatment. About 480 adults will be randomly assigned to receive either ZL-1310 or one of several standard treatments. The goal…

This early-phase trial tests an experimental drug called ST-001 (a form of fenretinide) in people with small cell lung cancer that has returned or stopped responding to standard treatments. The main goals are to find the safest dose and to watch for any side effects. About 44 par…

This study tests a new drug combination (chidamide, a PD-L1 inhibitor, and two chemotherapy drugs) as the first treatment for people with extensive-stage small-cell lung cancer. The goal is to see if it can slow cancer growth and improve survival. About 36 adults will receive the…

This study tests an experimental drug called alisertib in people with advanced small cell lung cancer whose disease has worsened after standard treatments. About 80 adults will receive alisertib alone to see if it can shrink tumors or slow the cancer. Researchers will also look f…

This early-phase trial tests a new drug called JANX008 in adults with advanced solid tumors (like lung, kidney, breast, or colorectal cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shri…

This study tests whether adding focused radiation to a standard drug combination (durvalumab plus chemotherapy) can help people with extensive-stage small cell lung cancer live longer without the cancer getting worse. About 49 adults who have not yet been treated for this advance…

This study is testing a new drug called DXC014 in people with advanced solid tumors, including small cell lung cancer, melanoma, and prostate cancer. The main goals are to check the drug's safety, find the best dose, and see if it can help shrink tumors. About 150 participants wi…

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors (like breast, lung, or ovarian cancer) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug shrinks tumors, either alone or combined with ot…

This early-phase study tests an experimental pill, NKT3964, designed to break down a protein (CDK2) that helps cancer cells grow. About 150 adults with advanced or metastatic solid tumors (including ovarian, endometrial, breast, gastric, and lung cancers) that have stopped respon…

This study tests a new drug called ZG006 in people with advanced small cell lung cancer or neuroendocrine carcinoma. The first part finds a safe dose, and the second part checks how well that dose shrinks tumors. About 265 adults aged 18-75 with good performance status are being …

This study tests a new medicine (PF-08634404) given with chemotherapy, then alone, for adults with transformed small cell lung cancer (T-SCLC), a rare and aggressive cancer. About 40 participants who have not yet been treated for T-SCLC will receive the drugs through IV infusions…

This study tests a combination of the drug serplulimab plus chemotherapy in people whose lung cancer changed from one type (EGFR-mutated non-small cell) to another (small cell) after prior treatment. About 66 adults aged 18-75 will take part. The goal is to see if this combo can …

This study tests an experimental oral drug called NEO212 in people with certain brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control the disease. About 134 adults will take part across t…

This study tests a new drug called KIVU-107 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and kill cancer cells while limiting harm to healthy cells. The main goals are to find the safest dose and check fo…

This study tests two experimental drugs, BL-B01D1 and SI-B003, alone or together in people with extensive-stage small cell lung cancer that has spread. The goal is to see if these treatments can shrink tumors or control the disease. About 100 adults aged 18 to 75 with good perfor…

This early-phase study tests a new drug called BL-M14D1 in people with advanced small cell lung cancer or other neuroendocrine cancers that have spread. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 120 adults will take part.

This early-stage trial tests a combination of two drugs, tarlatamab and ZL-1310, with or without a third drug (durvalumab) in people with small cell lung cancer that has come back after standard treatment. The main goal is to find safe doses and check for side effects. About 160 …

This study is testing an experimental drug called MGC026 in about 250 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Participants receive the drug by IV and are closely monitore…

This early-stage study tests a new targeted drug (NMS-03305293) combined with chemotherapy (temozolomide) in people with small cell lung cancer that has returned after prior treatments. The main goals are to check safety and find the right dose. About 10 participants will be enro…

This early-stage study is testing the safety of combining the drug talazoparib with low-dose chest radiation in people with extensive-stage small cell lung cancer. Up to 24 participants who have finished initial chemotherapy without their cancer getting worse will take talazopari…

This study tests a drug called onvansertib in people with small cell lung cancer whose cancer did not respond to or came back after chemotherapy. The drug blocks a protein that cancer cells need to repair themselves. About 37 participants will take the drug to see if it shrinks t…

This study tests whether the experimental drug ZG006 can help people with relapsed small cell lung cancer live longer compared to standard chemotherapy. About 420 adults aged 18 to 75 who are in fairly good health will be randomly assigned to receive either ZG006 or a chemotherap…

This study tests a new drug, ABBV-706, combined with atezolizumab against standard treatment for people with extensive-stage small cell lung cancer that hasn't been treated yet. About 180 adults will receive either the new combination or standard care to find the best dose and se…

This study tests an experimental drug called GV20-0251 in adults with advanced solid tumors (like lung, head and neck, or colon cancer) that have stopped responding to standard therapies. The goal is to see if the drug can shrink tumors or slow their growth. About 350 participant…

This early-phase trial tests an investigational drug called SYS6043 in adults with advanced or metastatic solid tumors that have spread or no longer respond to standard treatments. The main goals are to find a safe dose, understand side effects, and see if the drug can slow tumor…

This study is testing a new drug combination (YL201 and ivonescimab) in people with advanced solid tumors, including certain lung cancers. The goal is to see if the combination is safe and can shrink tumors. About 260 adults will take part, and the study is currently recruiting.

This study tests a new drug, ifinatamab deruxtecan, against standard treatments for people whose small cell lung cancer has returned. About 540 adults with advanced disease will be randomly assigned to receive the new drug or a doctor-chosen therapy. The goal is to see if the new…

This early-stage trial tests a new drug, NN3201, designed to attack cancer cells that have a specific marker called c-Kit. The study includes people with advanced or spreading cancers like gastrointestinal stromal tumors (GIST), small-cell lung cancer, and others. The main goal i…

This study tests whether adding trilaciclib to the standard drug lurbinectedin can lower the risk of dangerous low white blood cell counts (neutropenia) in people with advanced small cell lung cancer that has stopped responding to initial treatment. About 30 adults will receive t…

This study tests a new drug called ZG006 combined with standard immunotherapy (with or without chemotherapy) as a first treatment for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and to find the right dose. About 100 adults age…

This study compares a powerful 7T MRI to standard 1.5T/3T scans to see if it can detect very small brain metastases earlier in people with small-cell lung cancer who choose not to have preventive brain radiation. About 20 adults will get both types of scans over time. The goal is…

This study is testing a new imaging agent called 18F-T2, which targets a protein (CAIX) found on many solid tumors. About 200 adults with cancers like kidney, bladder, colorectal, or lung cancer will receive a PET/CT scan using this agent. The goal is to see if it can find tumors…

This study tests a new radioactive probe called PFD3 that targets a protein (DLL3) found on small cell lung cancer cells. Using PET/CT scans, doctors hope to see tumors more clearly and assess the cancer's spread. About 30 adults with confirmed small cell lung cancer will receive…

This study is testing a new imaging agent called 89Zr-DFO-SC16.56 to see if it can safely and effectively highlight small cell lung cancer tumors on PET/CT scans. The agent targets a protein called DLL3 found on these cancer cells. About 53 people with small cell lung cancer or r…

This study looks at whether people with advanced small cell lung cancer can be safely monitored at home after receiving the drug tarlatamab, instead of staying in the hospital. About 70 adults will take part, and researchers will track how many days they spend in the hospital ver…

This study tests whether a special immune-boosting nutrition drink can lower the chance of severe throat and esophagus inflammation (esophagitis) in lung cancer patients getting chest radiation. About 121 adults with lung cancer will either receive standard care or the immunonutr…

This study collects tumor samples, blood, and health information from 2,000 adults with certain lung and thymic cancers. The goal is to better understand these diseases and support future research. Participants do not receive treatment as part of this study.

This study observes 200 people with extensive stage small cell lung cancer to learn how genetic markers in tumors and blood change over time. Researchers will collect tissue and blood samples during standard treatment to see if certain subtypes relate to better or worse outcomes.…